trending Market Intelligence /marketintelligence/en/news-insights/trending/jaHkQWgVwuC3nd_TjuJwfA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Shandong Weigao Group Medical Polymer, partners sign capital increase deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Shandong Weigao Group Medical Polymer, partners sign capital increase deal

Shandong Weigao Group Medical Polymer Company Ltd, its existing joint venture partners and Nikkiso Co. Ltd. entered into the capital increase agreement.

Under the agreement, Nikkiso will subscribe for additional capital in Shandong Weigao subsidiary Weigao Blood Purification for a total consideration of 100 million Chinese yuan.

After the capital increase closes, Nikkiso and the Shandong Weigao will hold 5.0% and 46.87%, respectively, of the enlarged registered capital of Weigao Blood Purification. Further, upon closing, the subsidiary's board will expand to five members from three.

Xia Lie Bo resigned as executive director of Shandong Weigao to focus on the development of the blood purification business.

Shandong Weigao's joint venture partners include Weihai Kaide Information Technology Center LLP, Chen Lin, Xia Lie Bo and Shanghai Weike Investment Co. Ltd. The partners hold about 50.66% of the equity interest in Weigao Blood Purification.

As of Dec. 4, US$1 was equivalent to 6.62 Chinese yuan.